Stockscreener 앱 받기
2.64
8.65%
-0.25
시간 외 거래:
2.64
전일 마감가:
$2.89
열려 있는:
$2.87
하루 거래량:
1.03M
Relative Volume:
1.35
시가총액:
$98.57M
수익:
-
순이익/손실:
$-144.01M
주가수익비율:
-0.6584
EPS:
-4.01
순현금흐름:
$-113.02M
1주 성능:
-20.96%
1개월 성능:
-32.82%
6개월 성능:
-63.79%
1년 성능:
-85.18%
1일 변동 폭
$2.58
$2.9599
1주일 범위
$2.58
$3.34
52주 변동 폭
$2.58
$18.50
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
900 MIDDLEFIELD ROAD, REDWOOD CITY
BMEA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
2.64 | 98.57M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion reports inducement grant under Nasdaq listing rule - TipRanks
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Biomea Fusion Says Franco Valle Resigns As CFO -February 28, 2025 at 04:16 pm EST - Marketscreener.com
Biomea Fusion to Unveil New Icovamenib Data at the 18th - GlobeNewswire
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes - The Manila Times
Can This Diabetes Drug Work Long After You Stop Taking It? Biomea's Surprising Clinical Results - StockTitan
Biomea Fusion, Inc. (BMEA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Biomea Fusion stock hits 52-week low at $3.22 amid market challenges - Investing.com India
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Drops By 12.6% - MarketBeat
Biomea Fusion, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsBMEA - ACCESS Newswire
Promising US Penny Stocks To Watch In February 2025 - Simply Wall St
SG Americas Securities LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Insider Buyers Lose Additional US$78k As Biomea Fusion Dips To US$126m - Simply Wall St
Biomea Fusion stock hits 52-week low at $3.58 amid sharp decline - MSN
Biomea Fusion stock hits 52-week low at $3.58 amid sharp decline By Investing.com - Investing.com South Africa
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives $39.36 Average Price Target from Brokerages - MarketBeat
Biomea Fusion Inc (BMEA) Stock: A Look at the Analyst Recommendations - The News Heater
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Expands By 6.2% - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) is a favorite amongst institutional investors who own 51% - Yahoo Finance
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Barclays PLC Purchases 24,162 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Become a Diabetes & Obesity Medicines Company - GlobeNewswire
Biomea Fusion Pivots to Diabetes Focus After Breakthrough Drug Shows 1.5% HbA1c Reduction - StockTitan
Biomea Fusion (NASDAQ:BMEA) Earns “Buy” Rating from D. Boral Capital - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of “Buy” from Analysts - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Analysts - MarketBeat
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Recent uptick might appease Biomea Fusion, Inc. (NASDAQ:BMEA) institutional owners after losing 75% over the past year - Simply Wall St
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study - GlobeNewswire
Biomea's Icovamenib Boosts Semaglutide Effects: 11.5% Extra Weight Loss, 43% More Muscle Mass - StockTitan
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Here’s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Biomea Fusion CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Raises Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Barclays PLC Increases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update - Defense World
State Street Corp Decreases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) – Analysts’ Weekly Ratings Changes - Defense World
Biomea Fusion Advances Diabetes Treatment with Positive Study Results - TipRanks
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):